drugset / Trial / NCT00220766

Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients

NCT00220766

Phase 3 Completed 100 enrolled Grifols Therapeutics LLC
RandomizedCrossoverSingle-blindTreatment

Summary

The objective of this study is to determine if the safety and tolerability of Immune Globulin Intravenous (Human), 10% caprylate/chromatography (IGIV-C)purified is similar when infused at two different infusion rates. The primary objective is to compare the incidence and severity of all infusion related adverse events when IGIV-C, 10% is administered at a rate of 0.14 mL/kg/min compared to a rate of 0.08 mL/kg/min after a single daily infusion.

Timeline

Start
2002-08
Primary completion
2002-08
Completion
2004-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 400 mg/kg Intravenous
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 600 mg/kg Intravenous
Background Dextrose Unknown 5 %